From undruggable to actionable: advances in KRAS targeting in colorectal cancer
KRAS (Kristen rat sarcoma viral oncogene homolog) mutations occur in approximately 40–50% of metastatic colorectal cancer (CRC) cases and have long been associated with resistance to anti-epidermal growth factor receptor (EGFR) therapies and poor clinical outcomes. Historically considered...
Gorde:
| Egile Nagusiak: | , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Academia.edu Journals
2026-04-01
|
| Saila: | Academia Oncology |
| Sarrera elektronikoa: | https://www.academia.edu/165525801/From_undruggable_to_actionable_advances_in_KRAS_targeting_in_colorectal_cancer |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|